Pharvaris NV has released its financial results for the first quarter of 2025, reporting a loss of €46.3 million, compared to a loss of €28.0 million for the same period last year. This resulted in a basic and diluted loss per share of €0.85, an increase from €0.52 in the previous year. Research and Development (R&D) expenses rose significantly to €30.9 million from €18.5 million, and General and Administrative (G&A) expenses increased to €11.3 million from €9.8 million year-on-year. The company's liquidity position, comprising cash and cash equivalents, was reported at €236 million as of March 31, 2025, down from €281 million at the end of 2024. In terms of business updates, Pharvaris continues to advance its clinical studies, with enrollment ongoing in the CHAPTER-3 pivotal Phase 3 study of deucrictibant for the prophylaxis of HAE attacks, with topline data expected in the second half of 2026. Additionally, the RAPIDe-3 pivotal Phase 3 study for on-demand treatment of HAE attacks is accumulating data, bolstering confidence in clinical timelines. The company has also received TQT study waivers from the FDA for both the extended-release and immediate-release formulations of deucrictibant. Upcoming investor events include a management call on June 4 and a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 11.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.